Mark F. Brady - Researcher Profile | RDL Research Database

Publications

2 shown

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

Michael A. Bookman , Mark F. Brady , William P. McGuire +13 more

Purpose To determine if incorporation of an additional cytotoxic agent improves overall survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelia...

2009 Journal of Clinical Oncology 696 citations

Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

Franco M. Muggia , Patricia S. Braly , Mark F. Brady +6 more

PURPOSE: To assess progression-free survival (PFS) and overall survival (OS) in patients with suboptimally debulked epithelial ovarian cancer receiving cisplatin (100 mg/m 2 ) o...

2000 Journal of Clinical Oncology 616 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 1,312
Institution: Australia New Zealand Gynaecological Oncology Group

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-6700-2981

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.